ATTAIN study: Efficacy of abatacept in patients with rheumatoid arthritis and inadequate response to anti-TNF-α;Estudio ATTAIN: Eficacia del abatacept en pacientes con artritis reumatoide activa y respuesta inadecuada a antagonista de TNF-α

Reumatologia Clinica Suplementos

Volumn 1, Issue 2, 2006, Pages 34-43

  Fernandez Lopez C ^a   Blanco, F J ^a  

^a HOSPITAL JUAN CANALEJO   (Spain)

Author keywords

Abatacept; Anti TNF therapy; ATTAIN; Inadequate response to anti TNF therapy

Indexed keywords

ABATACEPT; ADALIMUMAB; AZATHIOPRINE; B7 ANTIGEN; CD28 ANTIGEN; CD86 ANTIGEN; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PENICILLAMINE; PLACEBO; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ABSCESS; ADULT; ARTICLE; BRONCHITIS; CLINICAL FEATURE; CLINICAL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DIARRHEA; DISEASE SEVERITY; DIVERTICULITIS; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; IMMUNOGENICITY; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NAUSEA; OSTEOMYELITIS; PAIN; PHARYNGITIS; PHASE 3 CLINICAL TRIAL; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; RHEUMATOID ARTHRITIS; SEPSIS; SINUSITIS; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 34548727959     PISSN: 18863604     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Grassi W, De Angelis R, Lamanna G, Cervini C. The clinical features of rheumatoid arthritis. Eur J Radiol. 1998;27 Suppl 1:18-24.
2. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med. 2001;344:907-16.
3. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the Management of Rheumatoid Arthritis. Arthritis Rheum. 2002;46:328-46.
4. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003;48:35-45.
5. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999;340:253-9.
6. Emery P. The therapeutic potential of costimulatory blockade with CTLA4Ig in rheumatoid arthritis. Expert Opin Investig Drugs. 2003;12:673-81.
7. Collins AV, Brodie DW, Gilbert RJ, Iaboni A, Manso-Sancho R, Walse B, et al. The interaction properties of costimulatory molecules revisited. Immunity. 2002;17:201-10.
8. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med. 1991;174:561-9.
9. Moreland LW, Alten R, Van den Bosch F, Appelboom T, Leon M, Emery P, et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum. 2002;46:1470-9.
10. Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med. 2003;349:1907-15.
11. Kremer JM, Dougados M, Emery P, Durez P, Sibilia J, Shergy W, et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: 12-month results of a phase IIB, double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005;52:2263-71.
12. Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, et el. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med. 2005;353:1114-23.
13. Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F. The American College of Rheumatology: 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum. 1992;35:498-502.
14. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology: preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38:727-35.
15. Pincus T, Summey JA, Soraci SA Jr, Wallston KA, Hummon NP. Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis Rheum. 1983;26:1346-53.
16. Felson DT, Anderson JJ, Lange MLM, Wells G, LaValley MP. Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures rather than twenty percent? Arthritis Rheum. 1998;41:1564-70.
17. Van Riel P. How to use the DAS28. Acceso el 1 junio 2006. Disponible en: http://www.das-score.nl/www.das-score.nl/howto1.htm
18. Fransen J, Creemers MC, Van Riel PL. Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology (Oxford). 2004;43:1252-5.
19. Vrijhoef HJ, Diederiks JP, Spreeuwenberg C, Van der Linden S. Applying low disease activity criteria using the DAS28 to assess stability in patients with rheumatoid arthritis. Ann Rheum Dis. 2003;62:419-22.
20. Ware JE, Kosinski M. SF-36 physical & mental health summary scales: a manual for users of version 1. 2nd ed. Lincoln, RI: QualityMetric; 2001.